Побочные явления при применении противоэпилептических средств

Е.А. Ушкалова


  1. World Health Organization. Epilepsy: etiology, epidemiology and prognosis. Geneva, Switzerland, June 1997; health communications and public relations fact sheet no. 165. Available from http://www.who.int/inf-fs/en/fact165.html.
  2. Dooley M, Plosker GL. Levetiracetam: a review of its adjunctive use in the management of partial onset seizures. Drugs 2000;60:871-93.
  3. Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985;313:145-51.
  4. Emilien G, Maloteaux JM. Pharmacological management of epilepsy. Mechanism of action, pharmacokinetic drug interactions, and new drug discovery possibilities. Int J Clin Pharmacol Ther 1998;36:181-94.
  5. Wallace SJ. A comparative review of the adverse effects of anticonvulsants in children with epilepsy. Drug Saf 1996;15:378-93.
  6. Sabers A, Gram L. Newer anticonvulsants: comparative review of drug interactions and adverse effects. Drugs 2000;60:23-33.
  7. Chadwick D. Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Vigabatrin European Monotherapy Study Group. Lancet 1999;354:13-9.
  8. Guberman A. Vigabatrin. Can J Neurol Sci 1996;23:S13-S17.
  9. Levinson DF, Devinsky O. Psychiatric adverse events during vigabatrin therapy. Neurology 1999;53:1503-11.
  10. Wong IC, Lhatoo SD. Adverse reactions to new anticonvulsant drugs. Drug Saf 2000;23:35-56.
  11. Baulac M, Arzimanoglou A, Semah F, Cavalcanti D. [Therapeutic options provided by new antiepileptic drugs]. Rev Neurol (Paris) 1997;155:21-33.
  12. Engel J Jr, Pedley TA, eds. Epilepsy: A Comprehensive Textbook. Philadelphia, Lippincott-Raven; 1997:1544.
  13. Yanai S, Hanai T, Narazaki O. Treatment of infantile spasms with zonisamide. Brain Dev 1999;21:157-61.
  14. Bourdet SV, Gidal BE, Alldredge BK. Pharmacologic management of epilepsy in the elderly. J Am Pharm Assoc 2001;41:421-36.
  15. Cramer JA, Mattson RH. Phenobarbital: toxicity. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic Drugs. 4th ed. New York, NY: Raven Press; 1995:409-20.
  16. Guerrini R, Belmonte A, Genton P. Antiepileptic drug-induced worsening of seizures in children. Epilepsia 1998;39:S2-S10.
  17. Perucca E, Gram L, Avanzini G, Dulac O. Antiepileptic drugs as a cause of worsening seizures. Epilepsia 1998;39:5-17.
  18. Scahpel G, Chadwick D. Tiagabine and nonconvulsive status epilepticus. Seizure 1996;5:153-6.
  19. Dreifuss FE. Valproate: toxicity. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic Drugs. 4th ed. New York, NY: Raven Press; 1995:641-8.
  20. Armon C, Shin C, Miller P, et al. Reversible parkinsonism and cognitive impairment with chronic valproate use. Neurology 1996;47:626-35.
  21. Taylor JW, Murphy MJ, Rivey MP. Clinical and electrophysiologic evaluation of peripheral nerve function in chronic phenytoin therapy. Epilepsia 1985;26:416-20.
  22. Krauss G, Crone N. Non-CNS side effects of antiepileptic drugs. http://www.medscape.com/Medscape/Neurology/TreatmentUpdate/2000/tu02/public/toc-tu02.html.
  23. Castillo S, Schmidt DB, White S. Oxcarbazepine add-on for drug-resistant partial epilepsy (Cochrane Review). In: The Cochrane Library, 1,2001. Oxford: Update Software. Ramaratnam S, Marson AG, Baker GA.
  24. Lamotrigine add-on fordrug-resistant partial epilepsy (Cochrane Review). In: The Cochrane Library, 1,2001. Oxford: Update Software.
  25. Glauser TA. Topiramate. Epilepsia 1999;40(suppl. 5):S71-S80.
  26. Wild JM, Martinez C, Reinshagen G, Harding GF. Characteristics of a unique visual field defect attributed to vigabatrin. Epilepsia 1999;40:1784-94.
  27. Miller NR, Johnson MA, Paul SR, et al. Visual dysfunction in patients receiving vigabatrin: clinical and electrophysiologic findings. Neurology 1999;53:2082-7.
  28. Nousiainen I, Mantyjarvi M. Visual function in patients treated with the GABAergic anticonvulsant drug tiagabine. Clin Drug Invest 2000;6(6).
  29. Faught E, Morris G, Jacobson M, et al. Adding lamotrigine to valproate: incidence of rash and other adverse effects. Postmarketing Antiepileptic Drug Survey (PADS) Group. Epilepsia 1999;40:1135-40.
  30. Chadwick D, Shaw MD, Foy P, et al. Serum anticonvulsant concentrations and the risk of drug induced skin eruptions. J Neurol Neurosurg Psychiatry 1984;47:642-4.
  31. Kramlinger KG, Phillips KA, Post RM. Rash complicating carbamazepine treatment. J Clin Psychopharmacol 1994;14:408-13.
  32. Guberman AH, Besag FM, Brodie MJ, et al. Lamotrigine-associated rash: risk/benefit considerations in adsults and children. Epilepsia 1999;40:985-91.
  33. Pellock JM. Overview of lamotrigine and the new antiepileptic drugs: the challenge. J Child Neurol 1997;12(suppl. 1):S48-S52.
  34. Tavenor SJ, Wong ICK, Newton R, et al. Rechallenge with lamotrigine after initial rash. Seizure 1995;4:67-71.
  35. Schumberger E, Chavez F, Palacios L, et al. Lamotrigine in treatment of 120 children with epilepsy. Epilepsia 1994;35:359-67.
  36. Dam M, Ekberg R, L_yning, et al. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 1989;3:70-6.
  37. Bill PA, Vigonius U, Pohlmann H, et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res 1997;27:195-204.
  38. Christe W, Kramer G, Vigonius U, et al. A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res 1997;26:451-60.
  39. Champion RH, Burton JL, Ebling FGJ. Textbook of Dermatology. Fifth edition. London: Blackwell Science Publications, 1992:2986-7.
  40. Fritsch PE, Ruiz-Maldanado R. Stevens-Johnson syndrome-toxic epidermal necrolysis. In: Freedberg IM, Fitzpatrick TB, eds. Dermatology in General Medicine. New York: McGraw Hill; 1999:644-653.
  41. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994;331:1272-85.
  42. Medsafe Editorial Team. Potentially Serious Adverse Effects of Carbamazepine: Blood Dyscrasias and Skin Rash. Prescriber Update No. 18, June 1999.
  43. Rzany B, Correia O, Kelly JP, et al. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions. Lancet 1999;353:2190-4.
  44. Schlienger RG, Shapiro LE, Shear NH. Lamotrigine-induced severe cutaneous adverse reactions. Epilepsia 1998;39:S22-S26.
  45. Wong IC, Mawer GE, Sander JW. Factors influencing the incidence of lamotrigine-related skin rash. Ann Pharmacother 1999;33:1037-42.
  46. Schmidt D, Kramer G. The new anticonvulsant drugs. Implications for avoidance of adverse effects. Drug Saf 1994;11:422-31.
  47. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994;331:1272-85.
  48. Patterson R, Miller M, Kaplan M, et al. Effectiveness of early therapy with coritcosteroids in Stevens-Johnson syndrome: experience with 41 cases and a hypothesis regarding pathogenesis. Ann Allergy 1994;73:27-34.
  49. Kelemen JJ, Cioffi WG, McManus WF, et al. Burn center care for patients with toxic epidermal necrolysis. J Am Coll Surg 1995;180:273-8.
  50. Schachter SC. The next wave of anticonvulsants: focus on levetiracetam, oxcarbazepine and zonisamide. CNS Drugs 2000;14:229-49.
  51. Drory VE, Korczyn AD. Hypersensitivity vasculitis and systemic lupus erythematosus induced by anticonvulsants. Clin Neuropharmacol 1993;16:19-29.
  52. Knowles SR, Shapiro LE, Shear NH. Anticonvulsant hypersensitivity syndrome: incidence, prevention and management. Drug Safety 1999;21:489-501.
  53. Havill S. Anticonvulsant Hypersensitivity Syndrome. Prescriber Update No. 16, April 1998
  54. Ragucci MV, Cohen JM. Gabapentin-induced hypersensitivity syndrome. Clin Neuropharmacol 2001;24:103-5.
  55. Vittorio CC, Muglia JJ. Anticonvulsant hypersensitivity syndrome. Arch Int Med 1995;155:2285-93.
  56. Ray-Chaudhuri K, Pye IF, Boggild M. Hypersensitivity to carbamazepine presenting with a leukemoid reaction, eosinophilia, erythroderma and renal failure. Neurology 1989;39:436-8.
  57. Spielberg SP, Gordon GB, Blake DA, et al. Predisposition to phenytoin hepatotoxicity assessed in vitro. N Engl J Med 1981;305:722-7.
  58. Gennis MA, Vemuri R, Burns EA, et al. Familial occurrence of hypersensitivity to phenytoin. Am J Med 1991;91:631-4.
  59. Silverman AK, Fairley J, Wong RC. Cutaneous and immunologic reactions to phenytoin. J Am Acad Dermatol 1988;18:721-41.
  60. Pellock JM. Felbamate. Epilepsia 1999;40(suppl. 5):S57-S62.
  61. Tohen M, Castillo J, Baldessarini RJ, et al. Blood dyscrasias with carbamazepine and valproate: a pharmacoepidemiological study of 2,228 patients at risk. Am J Psychiatry 1995;152:413-8.
  62. Beydoun A, Sackellares JC, Shu V. Safety and efficacy of divalproex sodium monotherapy in partial epilepsy: a double-blind, concentration-response design clinical trial. Depakote Monotherapy for Partial Seizures Study Group.Neurology. 1997;48:182-8.
  63. Temkin NR, Dikmen SS, Anderson GD, et al. Valproate therapy for prevention of posttraumatic seizures: a randomized trial. J Neurosurg 1999;91:593-600.
  64. Wong IC, Mawer GE, Sander JW. Adverse event monitoring in lamotrigine patients: a pharmacoepidemiologic study in the United Kingdom. Epilepsia 2001;42:237-44.
  65. Camfield C, Camfield P, Smith E, Tibbles JA. Asymptomatic children with epilepsy: little benefit from screening for anticonvulsant-induced liver, blood, or renal damage. Neurology 1986;36:838-841.
  66. Haidukewych D, John G. Chronic valproic acid and coantiepileptic drug therapy and incidence of increases in serum liver enzymes. Ther Drug Monit. 1986;8:407-10.
  67. Sano J, Kawada H, Yamaguchi N, et al. Effects of phenytoin on serum gamma-glutamyl transpeptidase activity. Epilepsia 1981;22:331-38.
  68. Dreifuss FE, Langer DH. Hepatic considerations in the use of antiepileptic drugs. Epilepsia 1987;28:S23-S29.
  69. Kugoh T, Yamamoto M, Hosokawa K. Blood ammonia level during valproic acid therapy. Jpn J Psychiatry Neurol 1986;40:663-8.
  70. Zaccara G, Paganini M, Campostrini R, et al. Effect of associated antiepileptic treatment on valproate-induced hyperammonemia. Ther Drug Monit 1985;7:185-90.
  71. Asconape JJ, Penry JK, Dreifuss FE, et al. Valproate-associated pancreatitis. Epilepsia 1993;34:177-183.
  72. Binek J, Hany A, Heer M. Valproic-acid-induced pancreatitis. Case report and review of the literature. J Clin Gastroenterol 1991;13:690-3.
  73. Otusbo S, Huruzono T, Kobae H, et al. Pancreatitis with normal serum amylase associated with sodium valproate: a case report. Brain Dev 1995;17:219-21.
  74. Van Amelsvoort T, Bakshi R, Devaux CB, Schwabe S. Hyponatremia associated with carbamazepine and oxcarbazepine therapy: a review. Epilepsia 1994;35:181-8.
  75. Brewerton TD, Jackson CW. Prophylaxis of carbamazepine-induced hyponatremia by demeclocycline in six patients. J Clin Psychiatry 1994;55:249-51.
  76. Nielsen OA, Johannessen AC, Bardrum B. Oxcarbazepine-induced hyponatremia: a cross-sectional study. Epilepsy Res 1988;2:269-71.
  77. Shorvon SD. Safety of topiramate: adverse events and relationships to dosing. Epilepsia 1996;37:S18-S22.
  78. Leppik IE. Zonisamide. Epilepsia 1999;40(suppl. 5):S23-S29.
  79. Yagi K, Seino M. Methodological requirements for clinical trials in refractory epilepsies - our experience with zonisamide. Prog Neuropsychopharmacol Biol Psychiatry 1992;16:79-85.
  80. Leppik IE, Willmore LJ, Homan RW, et al. Efficacy and safety of zonisamide: results of a multicenter study. Epilepsy Res 1993;14:165-73.
  81. Tanaka E. Clinically significant pharmacokinetic drug interactions between antiepileptic drugs. J Clin Pharm Ther 1999;24:87-92.
  82. Benedetti MS.Enzyme induction and inhibition by new antiepileptic drugs: a review of human studies. Fundam Clin Pharmacol 2000;14:301-11.
  83. Pack AM, Morrell MJ. Adverse effects of antiepileptic drugs on bone structure: epidemiology, mechanisms and therapeutic implications.
  84. Pluskiewicz W, Nowakowska J. Bone status after long-term anticonvulsant therapy in epileptic patients:evaluation using quantitative ultrasound of calcaneus and phalanges. Ultrasound Med Biol 1997;23:553-8.
  85. Arch Neurol 2001;58:1352-1353,1369-1374.
  86. Cornelissen M, Steegers-Theunissen R, Kollee L, et al. Increased incidence of neonatal vitamin K deficiency resulting from maternal anticonvulsant exposure. Am J Obstet Gynecol 1993;168:923-7.
  87. Howe AM, Oakes DJ, Woodman PD, Webster WS. Prothrombin and PIVKA-II levels in cord blood from newborn exposed to anticonvulsants during pregnancy. Epilepsia 1999;40:980-984.
  88. Hey E. Effect of maternal anticonvulsant treatment on neonatal blood coagulation Arch Dis Child Fetal Neonatal Ed 1999;81:F208-F210.
  89. Kishi T, Fujita N, Eguchi T, Ueda K. Mechanism for reduction of serum folate by antiepileptic drugs during prolonged therapy. J Neurol Sci 1997;145:109-12.
  90. Dinesen H, Gram L, Andersen T, Dam M. Weight gain during treatment with valproate. Acta Neurol Scand 1984;70:65-9.
  91. Dean JC, Penry JK. Weight gain patterns in patients with epilepsy: comparison of antiepileptic drugs. Epilepsia 1995;36:72.
  92. Egger J, Brett EM. Effects of sodium valproate in 100 children with special reference to weight. BMJ 1981;283:577-81.
  93. Guberman A, Bruni J. Long-term open multicentre, add-on trial of vigabatrin in adult resistant partial epilepsy. The Canadian Vigabatrin Study Group. Seizure 2000;9:112-8.
  94. Krauss GL, Simmons-O'Brien E, Campbell M. Successful treatment of seizures and porphyria with gabapentin. Neurology 1995;45:594-5.
  95. Herzog AG. Reproductive endocrine considerations and hormonal therapy for men with epilepsy. Epilepsia 1991;32:S34-S37.
  96. Morrell MJ, Guldner GT. Self-reported sexual function and sexual arousability in women with epilepsy. Epilepsia 1996;37:1204-10.
  97. Stoffel-Wagner B, Bauer J, Flugel D, et al. Serum sex hormones are altered in patients with chronic temporal epilepsy receiving anticonvulsant medication. Epilepsia 1998;39:1164-73.
  98. Herzog AG, Klein P, Jacobs AR. Testosterone versus testosterone and testolactone in treating reproductive and sexual dysfunction in men with epilepsy and hypogonadism. Neurology 1998;50:782-4.
  99. Legro RS. Polycystic ovary syndrome: current and future treatment paradigms. Am J Obstet Gynecol 1998;179:S101-S108.
  100. Chappell KA, Markowitz JS, Jackson CW. Is valproate pharmacotherapy associated with polycystic ovaries? Ann Pharmacother 1999;33:1211-6.
  101. Harlow BL, Cramer DW, Baron JA, et al. Psychotropic medication use and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 1998;7:697-702.
  102. Surks MI, DeFesi CR. Normal serum free thyroid hormone concentrations in patients treated with phenytoin or carbamazepine. A paradox resolved. JAMA 1996;275:1495-8.
  103. Kenneback G, Bergfeldt L, Vallin H, et al. Electrophysiologic effects and clinical hazards of carbamazepine treatment for neurologic disorders in patients with abnormalities of the cardiac conduction system. Am Heart J 1991;121:1421-8.
  104. Shane-McWhorter L, Cerveny JD, MacFarlane LL, Osborn C. Enhanced metabolism of levonorgestrel during phenobarbital treatmentand resultant pregnancy. Pharmacotherapy 1998;18:1360-4.
  105. Sabers A, Gram L. Newer anticonvulsants: comparative review of drug interactions and adverse effects. Drugs 2000;60:23-33.
  106. Morrell MJ. The new antiepileptic drugs and women: efficacy, reproductive health, pregnancy, and fetal outcome. Epilepsia 1996;37(suppl. 6):S34-44.
  107. Eldon MA, Underwood BA, Randinitis EJ, Sedman AJ. Gabapentin does not interact with a contraceptive regimen of norethindrone acetate and ethinyl estradiol. Neurology 1998;50:1146-8.
  108. Федеральное руководство для врачей по использованию лекарственных средств (формулярная система). Выпуск II. Москва, 2001, с. 803-843.
  109. Wallace SJ. Newer antiepileptic drugs: advantages and disadvantages. Brain Dev 200;23:277-83.

Бионика Медиа